Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
NSC Norfolk Southern Corp
WM Waste Management Inc
ITOS Iteos Therapeutics Inc
CCLD CareCloud Inc
JEF Jefferies Financial Group Inc
RSASF Resaas Services Inc
VRNT Verint Systems Inc
TRHC Tabula Rasa HealthCare Inc
ILMN Illumina Inc
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Price
Delayed
$772.06
Day's Change
-8.80 (-1.13%)
Bid
--
Ask
--
B/A Size
--
Day's High
778.05
Day's Low
763.15
Volume
(Below Average)

Today's volume of 572,293 shares is on pace to be lower than REGN's 10-day average volume of 724,147 shares.

572,293

OLO 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Olo Inc. - OLO

10:50 pm ET November 25, 2022 (BusinessWire) Print

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 28, 2022 to file lead plaintiff applications in a securities class action lawsuit against Olo Inc. (NYSE: OLO), if they purchased the Company's shares between August 11, 2021 and August 11, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased shares of Olo and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-olo/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by November 28, 2022.

About the Lawsuit

Olo and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On August 11, 2022, the Company announced disappointing results for 2Q2022, disclosing lowered revenue guidance and a flat active location count due to the loss of 2,500 Subway locations resulting from Subway's implementation of direct integration with marketplaces, and that the Company expected the remaining Subway locations to also end their contracts by 4Q2022 or 1Q2023, which effects the Company claimed to have incorporated into its guidance months earlier without informing the market. On this news, shares of Olo stock plummeted approximately 36%, from a closing price of $12.99 per share on August 11, 2022, to a closing price of $8.26 per share on August 12, 2022.

The case is Pompano Beach Police and Firefighters' Retirement System v. Olo Inc., No. 1:22-cv-08228.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients - including public institutional investors, hedge funds, money managers and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221125005385/en/

SOURCE: Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com 
1-877-515-1850
comtex tracking

COMTEX_419717686/1006/2022-11-25T22:50:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.